SCHEMBL1403380

SCHEMBL1403380

O=C(O)/C=C/c1cccc(S(=O)(=O)NCc2ccccc2)c1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 4/20 0.80
HDAC8 Q9BY41 4/20 0.80
HDAC6 Q9UBN7 4/20 0.80
HDAC3 O15379 3/20 0.80
HDAC4 P56524 3/20 0.80
HDAC1 Q13547 3/20 0.80
HDAC7 Q8WUI4 3/20 0.80
HDAC10 Q969S8 3/20 0.80
HDAC11 Q96DB2 3/20 0.80
HDAC9 Q9UKV0 3/20 0.80
HDAC5 Q9UQL6 3/20 0.80
HTT P42858 1/20 0.57
KEAP1 Q14145 1/20 0.56
BRD4 O60885 1/20 0.52
ESR1 P03372 1/20 0.52
PTGS1 P23219 1/20 0.52
PDE4A P27815 1/20 0.52
PIK3CA P42336 1/20 0.52
HTR6 P50406 1/20 0.52
PDE4D Q08499 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1403382 1.00 HDAC2 (0.80) HDAC2HDAC8HDAC6HDAC3HDAC4
SCHEMBL1402922 0.90 HDAC2 (0.76) HDAC2HDAC8HDAC6HDAC3HDAC4
SCHEMBL1402920 0.90 HDAC2 (0.76) HDAC2HDAC8HDAC6HDAC3HDAC4
SCHEMBL8255162 0.89 HDAC2 (1.00) HDAC2HDAC8HDAC6HDAC3HDAC4
SCHEMBL1403064 0.88 HDAC2 (0.73) HDAC2HDAC8HDAC6HDAC3HDAC4
SCHEMBL1403063 0.88 HDAC2 (0.73) HDAC2HDAC8HDAC6HDAC3HDAC4
SCHEMBL1403278 0.87 AKR1C3 (0.63) HDAC2HDAC8HDAC6HDAC3HDAC4
SCHEMBL1403280 0.87 AKR1C3 (0.63) HDAC2HDAC8HDAC6HDAC3HDAC4
SCHEMBL1403341 0.87 MEN1 (0.66) HDAC2HDAC8HDAC6HDAC3HDAC4
SCHEMBL1403340 0.87 MEN1 (0.66) HDAC2HDAC8HDAC6HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1328510-B1 (E)-N-HYDROXY-3-(3-SULFAMOYL-PHENYL)-ACRYLAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE TOPOTARGET UK LTD (GB) 2013-11-20 EP disclosed
EP-2292593-A2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TopoTarget UK Limited (GB) 2011-03-09 EP disclosed
US-7557140-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2009-07-07 US disclosed
US-7557140-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2009-07-07 US disclosed
US-7557140-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2009-07-07 US disclosed
US-7407988-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2008-08-05 US disclosed
US-7407988-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2008-08-05 US disclosed
US-7407988-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2008-08-05 US disclosed
US-20080161401-A1 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2008-07-03 US disclosed
US-20080161401-A1 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2008-07-03 US disclosed
US-7183298-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2007-02-27 US disclosed
US-20070004806-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2007-01-04 US disclosed
US-20070004806-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2007-01-04 US disclosed
US-20070004806-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2007-01-04 US disclosed
US-20050107445-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors PROLIFIX LIMITED (GB) 2005-05-19 US disclosed
US-6888027-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2005-05-03 US disclosed
US-20050085515-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPO TARGET UK LIMITED, (GB) 2005-04-21 US disclosed
US-20040077726-A1 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors SWK FUNDING LLC 2004-04-22 US disclosed
EP-1328510-A2 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LTD. (GB) 2003-07-23 EP disclosed
WO-2002030879-A2 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LIMITED (GB) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107445-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC2 5/4885HDAC8 4/4885HDAC6 10/4885
US-20070004806-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC2 5/4885HDAC8 4/4885HDAC6 10/4885
US-20080161401-A1 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS HDAC1, HDAC11, HDAC3 HDAC2 5/4885HDAC8 4/4885HDAC6 10/4885
US-20040077726-A1 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors HDAC1, HDAC11, HDAC2 HDAC2 3/4885HDAC8 4/4885HDAC6 10/4885
US-20050085515-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC2 5/4885HDAC8 4/4885HDAC6 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.